November 20, 2026
Leukemia Acute Lymphoblastic Leukemia News

Frontline blinatumomab, ponatinib spares chemotherapy, transplant for patients with newly diagnosed Ph–positive B-ALL

Frontline treatment with blinatumomab plus ponatinib yielded deep, durable remissions in patients with Philadelphia–positive B-cell acute lymphoblastic leukemia, according to updated follow-up results from a phase 2 trial.

The trial, led by Lewis Fady Nasr, MD, MSc, of The University of Texas MD Anderson Cancer Center in Houston, was presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in the Journal of Clinical Oncology. 

The study enrolled 88 patients with newly diagnosed Ph–positive B-ALL to receive up to five cycles of blinatumomab with ponatinib 30 mg daily, reduced to 15 mg daily after a complete molecular response. Patients with a white blood cell count greater than 70×109/L received two cycles of high-dose methotrexate and cytarabine. Participants continued ponatinib for at least five years.

As of January 2026, the objective response rate was 96%, including a complete remission (CR) rate of 95%. Among evaluable patients, 95% achieved negative measurable residual disease, including 43% after one cycle. The median follow-up was three years, and 79% of patients remained in molecular remission without requiring allogeneic stem cell transplant. Of these patients, one received inotuzumab for positive MRD and one underwent chimeric antigen receptor T-cell therapy. Two patients underwent transplant during their first CR for persistent positive p190 transcripts.

Overall, 11 patients relapsed, including 10 with p190 transcripts, with a median time to relapse from CR of 20 months (range, 8-33). Among relapses, five were bone marrow only, five were central nervous system only, and one was extramedullary only. Three of the 11 relapsed patients died. Notably, seven out of the 11 relapsed patients had a baseline WBC greater than 70×109/L.

The median event-free survival and overall survival were not reached. The three-year EFS and OS rates were 79% and 89%, respectively. EFS and OS outcomes did not significantly differ based on transcript types nor MRD clearance after cycle one. The three-year cumulative incidence of relapse was 31% for patients with WBC greater than or equal to 70×109/L and 6.7% for those with WBC less than 70×109/L (P=.005). The cumulative incidence of relapse was 16% for patients with IKZF1–positive disease versus 21% for those with non-IKZF1 disease (P=.6).

The combination of blinatumomab and ponatinib as frontline therapy induced deep and durable responses and allowed most patients to avoid transplant. The rate of relapse in patients with high baseline WBC supports the use of risk-adjusted strategies, including increased intrathecal chemotherapy, high-dose chemotherapy in consolidation, and CAR T-cell therapy, Dr. Nasr and colleagues wrote.

Reference

Nasr LF, Goulart H, Short NJ, et al. Updated results of the chemotherapy-free regimen of blinatumomab and ponatinib in patients with newly diagnosed Philadelphia-positive B-cell acute lymphoblastic leukemia. J Clin Oncol 44, 6514-6514(2026). DOI:10.1200/JCO.2026.44.16_suppl.6514

 

Leave feedback about this

  • Quality
  • Price
  • Service

PROS

+
Add Field

CONS

+
Add Field